January 6, 2014Current Medical Research and Opinion
Cangrelor: an emerging therapeutic option for patients with coronary artery disease
Key result
Cangrelor combined with clopidogrel is relatively safe and more effective than standard clopidogrel in urgent and elective PCI, though it lacks a survival advantage.
Why the study?
Does cangrelor improve clinical outcomes compared to standard clopidogrel regimens in patients with coronary artery disease?
Population
Patients with coronary artery disease
Comparison
Cangrelor vs Standard clopidogrel regimen
Design
Systematic_review
Authors
Discussion
Loading...
Member takes
Implication
Supports cangrelor-clopidogrel in PCI for ischemic benefit; reinforces Level 1 evidence without survival impact.
Study Design
Type
Systematic Review
Structured PICO
Does cangrelor improve clinical outcomes compared to standard clopidogrel regimens in patients with coronary artery disease?
P
Population
Patients with coronary artery disease
I
Intervention
Cangrelor (intravenous, direct-acting P2Y12 antagonist)
C
Comparator
Standard clopidogrel regimen
O
Outcome
Clinical outcomes (ischemic events and safety)
Cangrelor offers a rapid-onset, quickly reversible intravenous P2Y12 inhibition option that may improve ischemic outcomes in PCI compared to clopidogrel, though evidence against newer oral agents is limited.
Limitations
- Lack of adequately powered studies assessing cangrelor co-administration either with prasugrel or ticagrelor
- Suboptimal design of some of the trials favoring cangrelor
- Potentially attenuated benefits with modern stent design
- Lack of survival advantage
- lack of adequately powered studies assessing cangrelor co-administration either with prasugrel or ticagrelor
- suboptimal design of some of the trials favoring cangrelor
- potentially attenuated benefits with modern stent design
- lack of survival advantage
Cite This Study
Kubica et al. (2014) conducted a systematic review in Coronary artery disease. Cangrelor vs. Clopidogrel was evaluated. Cangrelor combined with clopidogrel is relatively safe and more effective than standard clopidogrel in urgent and elective PCI, though it lacks a survival advantage.